U.S. Markets close in 3 hrs 13 mins

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
10.36-0.26 (-2.48%)
As of 12:46PM EDT. Market open.

Brooklyn ImmunoTherapeutics, Inc.

Building A
Suite 2100 140 58th Street
Brooklyn, NY 11220
United States
212 582 1199
http://www.brooklynitx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Howard J. Federoff M.D., Ph.D.CEO, Pres & DirectorN/AN/AN/A
Dr. Monil Shah M.B.A., Pharm.D.Chief Operating OfficerN/AN/AN/A
Dr. Kevin A. D'AmourChief Scientific OfficerN/AN/AN/A
Mr. Ronald Guido M.S.Chief Devel. OfficerN/AN/A1957
Ms. Lynn Sadowski Mason M.S.Exec. VP of Clinical OperationsN/AN/AN/A
Mr. Stephen R. GoldbergSec.N/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.

Corporate Governance

Brooklyn ImmunoTherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.